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Objectives The primary objective of this report was to describe the infrastructures and processes of
selected European and North American pre-hospital ﬁbrinolysis (PHL) programs. A secondary objec-
tive is to report the outcome data of the PHL programs surveyed.
Background Despite its beneﬁt in reducing mortality in patients with ST-segment elevation myocar-
dial infarction, PHL remained underused in North America. Examination of existing programs may
provide insights to help address barriers to the implementation of PHL.
Methods The leading investigators of PHL research projects/national registries were invited to re-
spond to a survey on the organization and outcomes of their afﬁliated PHL programs.
Results PHL was successfully deployed in a wide range of geographic territories (Europe: France,
Sweden, Vienna, England, and Wales; North America: Houston, Edmonton, and Nova Scotia) and was
delivered by healthcare professionals of varying expertise. In-hospital major adverse outcomes were
rare with mortality of 3% to 6%, reinfarction of 2% to 5%, and stroke of 2%.
Conclusions Combining formal protocols for PHL for some patients with direct transportation of
others to a percutaneous coronary intervention hospital for primary percutaneous coronary interven-
tion would allow for tailored reperfusion therapy for patients with ST-segment elevation myocardial
infarction. Insights from a variety of international settings may promote widespread use of PHL and
increase timely coronary reperfusion worldwide. (J Am Coll Cardiol Intv 2011;4:877–83) © 2011 by
the American College of Cardiology Foundation
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878Timely reperfusion through the administration of fibrino-
lytic therapy (FL) or primary percutaneous intervention
(PCI) is critical in the management of acute myocardial
infarction with ST-segment elevation (1,2). Compared with
in-hospital administration, pre-hospital administration of
FL (PHL) allows for earlier treatment and better survival
rates (3). Whereas primary PCI is the preferred reperfusion
therapy, PHL may be superior to primary PCI in reducing
mortality among patients with ST-segment elevation myo-
cardial infarction (STEMI) who present early (i.e., less than
2 h after the onset of symptoms) (4,5). For rural popula-
tions, PHL may be the only reperfusion strategy that can be
provided in a timely manner (6).
See page 884
PHL requires a complex pre-hospital system of care to
enable prompt and accurate recognition of STEMI and
skilled management of life-threatening complications of
PHL such as arrhythmia, major
bleeding, and stroke (6). Despite
this complexity, PHL has been en-
dorsed by the European Society of
Cardiology (7–9) and has been well
established in Europe for over 2
decades (7–9). In contrast, PHL is
available in very few American and
Canadian regions (10), despite the
larger territories and high propor-
tion of rural populations in these
countries compared with Europe
(10–12).
Insights on the infrastructures
and processes that support PHL
care in Europe and North America may assist other jurisdic-
tions to implement PHL systems of care. Based on the longer
European experience, patients who received PHL in these
regions would be likely to have more favorable survival rates
and fewer major complications than would patients treated by
less-experienced PHL programs. Therefore, European PHL
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infarctionChronic Disease. Dr. Stenestrand was the President of the RIKS-HIA Registry. Dr. Msurvival data may serve as an optimal benchmark for other
PHL programs. The primary objective of this article was to
describe the infrastructures and processes of selected European
and North American PHL programs. The secondary objective
was to report outcome data of the PHL programs surveyed.
Methods
Selection of PHL programs. We contacted cardiology experts
in STEMI treatment to inquire about available PHL programs
in Europe and North America. We obtained 100% response
from the leading investigators of the 7 PHL programs con-
tacted: England/Wales, France, Vienna, and Sweden from
Europe; Edmonton and Nova Scotia from Canada; and
Houston, Texas, from the United States.
Afﬁliated PHL research programs/national registries. All the
participating PHL programs had affiliated research projects
which were MINAP (Myocardial Ischemia National Audit
Project) in England/Wales (13), FAST-MI (French Reg-
istry on Acute ST-Elevation Myocardial Infarction) in
France (14), RIKS-HIA (Register of Information and
Knowledge About Swedish Heart Intensive Care Admis-
sions) in Sweden, Vienna-STEMI Registry in Vienna,
AMICO (Alliance for Myocardial Infarction Care Optimi-
zation) in Houston, Vital Heart Response in Edmonton,
and the Cardiovascular Health Nova Scotia Program in
Nova Scotia.
Data collection. PHL may have different impacts on
STEMI morbidity and mortality depending on the rural-
urban mix of the population served and access to hospitals
that can deliver alternate reperfusion therapy such as pri-
mary PCI. Most recent data relevant to each PHL program
included in this study on the territory and population served
were extracted from the official Website of United Nation
Statistics (available only for the year 2008) (15). We defined
“rural” as all “nonurban” regions with a population of less
than 1,000 persons, and a population density less than 400
persons per km2 (Organisation for Economic Co-operation
nd Development’s definition) (16). For jurisdictions other
han countries, we extracted population and geography data
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879in 2008, from the national statistical Websites that is, for
England and Wales (Office for National Statistics of Eng-
land) (17), for Nova Scotia and Edmonton (Statistics
Canada) (18), for Vienna (City of Vienna Information
Center) (19), and Houston (United States Census Bureau)
(20). Data on the number of hospitals, the proportion of
hospitals with PCI facilities (PCI-hospital), and the annual
incidence of STEMI within each jurisdiction were provided
by the leading investigators of the PHL programs surveyed.
In August 2008, we mailed a self-administered question-
naire (Online Appendix 1) to the lead investigators of 7
participating PHL programs. The questionnaire collected
data on pre-hospital services available, as well as informa-
tion on the infrastructure of the PHL program and how the
program worked (i.e., its processes). Questionnaires were
completed in full by all the surveyed programs in April
2009. We recontacted respondents in June 2010 to inquire
about recent modifications to the PHL programs.
Table 2. Interpretation and Transmission of Pre-Hospital ECG in 2010
Country
England and
Wales Sweden
Fran
Territor
Year pre-hospital ECG became available 2000 1990
% of ambulance personnel trained to
interpret ECG
100 100
Electronic transmission of ECG, % of
pre-hospital ECG
Not routinely
done
100
Failed electronic transmission of
pre-hospital ECG
Nonapplicable 1% No
Table 1. Characteristics of Countries, Provinces, and Cities With PHL Prog
Country
England/Wales Sweden
Fran
Territo
Total population (million) served by
the PHL program
54.5 9.0
Area (km2) served by PHL program 151,174 441,370
Population density, mean no.
persons/km2
360 21
Rural population, % of
total population
20 15
No. STEMI/year 27,000 6,000
No. STEMI/100,000 population 50 66
No. hospitals that provide STEMI care 224 74
No. hospitals with PCI facility (% of
hospitals that provide STEMI care)
98 (44) 29 (39)
Population per hospital with
PCI facility
556,122 310,344
*Data from Houston include surrounding areas and exclude STEMI patients who presented directly
NA not available; PCI percutaneous coronary intervention; STEMI ST-segment elevation mECG electrocardiogram.The investigators were also asked to report the aggregate
data since the initiation of the PHL program, as well as for
the years 2005 to 2008. Outcomes data in these recent three
years would be more clinically relevant than outcome data in
the past decade because there were numerous recent inno-
vations in the treatment of STEMI. Due to confidentiality
issues, we could not obtain individual patient data from the
PHL programs surveyed.
Results
There was marked variation in the proportion of the
population living in rural areas and the mean population
density in the areas surveyed (Table 1). The mean popula-
tion density varied from 16 persons/km2 in Nova Scotia to
,189 persons/km2 in Vienna. The proportion of the pop-
lation living in rural areas varied from 5% in Vienna to 45%
n Nova Scotia. Access to PCI-hospital was also limited in
Province City
cluding
d Corsica)
Edmonton, Alberta
(Canada)
Houston,
Texas
Nova Scotia
(Canada)
Vienna
(Austria)
2002 2005 2006 2000
100 100 32 100
100 100 100 Pilot
icable 5 20 10 Nonapplicable
in 2010
Province City
xcluding
d Corsica)
Nova Scotia
(Canada)
Houston,
Texas*
Edmonton, Alberta
(Canada)
Vienna
(Austria)
61.0 0.9 2.1 1.2 1.7
00 55,491 1,499 9,532 414
12 16 1,400 126 4,589
17 45 NA 15 5
00 NA 211 780 1,200
55 NA 10 65 70
23 8 30 5 6
57) 1 (12.5) 22 (73) 2 (40) 6 (100)
15 900,000 175,000 600,000 316,666
itals without using pre-hospital transportation services.
ial infarction.ce (Ex
ies an
1990
100
0
napplrams
ce (E
ries an
551,5
1
35,0
2
127 (
480,3
to hosp
uST-segm
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880Nova Scotia with only 1 PCI-hospital in this Canadian
province (ratio of 900,000 persons/PCI-hospital compared
with 175,000 persons/PCI-hospital in Houston, Texas).
In most surveyed countries except for Sweden, pre-
hospital ECG were available only since the year 2000 (Table 2).
Most ambulance personnel were trained to interpret ECG.
In Vienna and France, 95% and 100%, respectively, of
ambulances were staffed with physicians (Table 3), all
other PHL programs surveyed had paramedics and nurses
(Sweden) able to provide advanced cardiac life support (i.e.,
advanced care paramedics). The PHL programs in London,
Vienna, Houston, Edmonton, Sweden, and Halifax had inte-
grated regional networks to facilitate direct transfer of patients
for primary PCI (Table 4). In Vienna and Sweden, all
STEMI patients were transported directly to a PCI-hospital
for primary PCI, except for patients who lived in very
remote rural areas in Sweden. In England/Wales, at the
Table 3. Expertise of the Personnel Responsible for Pre-Hospital STEMI Ca
Country
England and
Wales Sweden
France (E
Territories an
Presence of medical doctors in
the ambulances, % of
ambulances
0 0 100
Advanced care paramedics* in
the ambulances, % of
ambulances
100 100 100
Professionals who provide
telephonic guidance for
STEMI management
ER physicians or
CCU nurses
ER or CCU
physicians
Not app
*Advanced care paramedics are paramedics who can provide advanced cardiac life support indepe
CCU coronary care unit; ER emergency room affiliated to the pre-hospital services; STEMI
Table 4. Pre-Hospital Care of Patients With STEMI in 2010
Country
England and
Wales Sweden
France
Territorie
Routine transfer of patients
for primary PCI, % of
STEMI patients
100 for London, no routine
transfer for primary PCI
outside London
87 NA
Responsible to authorize
PHL
Paramedics ER physicians Physicians
ambul
Types of ﬁbrinolytic therapy,
% of patients who
received PHL
TPA: 0.15, Reteplase: 19.9,
TNK: 79.5
(1995–2008) SK: 4,
TPA: 11,
Reteplase: 62,
TNK: 24 since
2004 only
reteplase and
TNK were used
TNK: 100
Routine angiography after
PHL, % of patients who
received PHL
75 50PHL pre-hospital fibrinolysis, SK streptokinase; TNK tenecteplase; TPA tissue plasminogen activattime of this survey, there was no formal transportation
arrangement for primary PCI outside London. In the
greater London area, all STEMI patients were transported
directly for primary PCI. In Nova Scotia, direct transfer for
primary PCI was only possible for patients with STEMI
living in Halifax.
Except for England/Wales, where paramedics could in-
dependently initiate PHL, PHL could only be administered
after transmission of pre-hospital electrocardiogram (ECG)
and authorization from responsible physicians in the other
PHL programs (Table 4). In Houston, Nova Scotia, and
Edmonton, PHL was administered by paramedics; in Swe-
den, by ambulance nurses; and in France and Vienna, PHL
was administered by physicians in the ambulances.
We described the characteristics and outcomes of patients
who received PHL in Tables 5 and 6. Reinfarction was
ncommon with cumulative incidences that ranged from 2.4%
the Ambulance or by Telephone Assistance) in 2010
Province City
g
sica)
Nova Scotia
(Canada)
Houston,
Texas
Edmonton, Alberta
(Canada) Vienna (Austria)
0 0 0 95
51 100 100 5
ER physicians ER physicians ER physicians and
cardiologists
ER physicians and
cardiologists
.
ent elevation myocardial infarction.
Province City
uding
orsica)
Nova Scotia
(Canada)
Houston,
Texas
Edmonton, Alberta
(Canada) Vienna (Austria)
Only in Halifax 85 60 100
Physicians afﬁliated
with the
pre-hospital
services
ER physician Physicians afﬁliated
with the
pre-hospital
services
Physicians in the
ambulances
TPA: 11, Reteplase:
4.2, TNK: 82.2,
undetermined: 3.2
Reteplase: 100 TNK: 100 TNK: 100
100% in only Halifax 100 90 90re (in
xcludin
d Cor
licable
ndently(Excl
s and C
in the
ances
85or; other abbreviations as in Tables 1 and 3.
s
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881(France) to 5.8% (England/Wales). Less than 2% of PHL
patients (0.6% in most programs) experienced in-hospital
troke. The French PHL program had the lowest mortality at
.7% in-hospital and 4.5% at 1 year, whereas Sweden had the
ighest in-hospital mortality at 6.5% and 10.7% at 1 year.
iscussion
Although the efficacy and safety of PHL were demonstrated
in several randomized clinical trials (RCTs) (2–5), the
generalizability of these results is limited by differences in
characteristics of patients and systems of care in the “real-
life” context. Real-life patients are often older and sicker
with more comorbidities than patients enrolled in RCTs
(21). Because of their generally larger samples sizes and longer
follow-up durations than RCTs (22,23), data from cohort
studies, such as those reported in this article, may offer
invaluable insights into the real-life effectiveness of PHL.
There are several barriers to PHL implantation in North
America (24). First, the cost of a PHL program may be
prohibitive for many pre-hospital agencies (24). Further-
more, emergency physicians may be reluctant to authorize
PHL for patients whom they have not yet evaluated for fear
of litigation. There may also be misperception that PHL is
not necessary considering that 79% of Americans and 59%
of Canadians live within an hour of a PCI-hospital (13,26)
Table 5. Characteristics of Patients Who Received PHL Therapy
England and Wales
2003–2008 France 2000 France 20
n 12,888 180 331
Mean age, yrs 62.1 11.6 59.4 12.9 60.5 12
Women, % 21.8 16.0 20.5
Mean systolic blood pressure,
mm Hg
133 25 127 23 130 25
Prior myocardial infarction, % 11 10 9
Prior PCI, % 13 7 7
Prior CABG, % 2 2 2
Prior CVA, % 2 1 1
Values are n, mean SD, or %.
CABG coronary artery bypass graft; CVA cerebrovascular accident; other abbreviations as in
Table 6. Major Adverse Events in Patients Who Received PHL Therapy
England/Wales
2003–2008 France 2000 France 2005
Major bleed, % 0.9* NA 1.2
Reinfarction, % 5.2† 2.8 2.4
Stroke, % 0.5‡ 1.1 0.6
In-hospital mortality, % 3.3§ 3.3 2.7
1-yr mortality, % 6.9 5.6 4.5
*Data available for 11,170 patients. †Reinfarction was ascertained only since 2005. ‡Data availab
(2007–2008).NA not available.and therefore should be able to undergo primary PCI in a
timely manner. However, the preceding estimate was based
purely on geographic distance and without consideration of
bad weather and traffic congestion. Despite the large num-
ber of PCI-hospitals and shorter distances to PCI-hospitals
in Europe, PHL remains a valuable reperfusion strategy
endorsed by the European Society of Cardiology (7–9).
Pre-hospital ECG is an essential prerequisite for PHL
and endorsed by the American Heart Association and
American College of Cardiology (2). However, only a
minority of North American pre-hospital medical services
can perform ECGs in the ambulances (10,11). Transmission
problems might have further prevented implementation of
pre-hospital ECG in many regions. Among the PHL pro-
grams surveyed, ECG interpretation in the ambulances can
either be automated (i.e., interpreted by a computer) or
undertaken by paramedics or by nurses. Although ECG
transmission could be helpful for patients with unclear diag-
noses, well-trained paramedics and nurses could diagnose and
treat most STEMI successfully without ECG transmission.
The outcomes reported in this article provided important
insights into the effectiveness and safety of PHL within
several different contexts and time spans. These results were
similar to the outcomes reported by other American PHL
programs (26). Denktas et al. (26) reported similarly low
Edmonton, Alberta
2000–2002
Vienna
2003–2008
Vienna
2005–2008
Sweden
1995–2008
Sweden
2005–2008
119 350 191 6,643 883
61.3 58 12 57 12 66.4 11.4 66.7 11.3
24.4 26.6 28.6 28.0 27.0
120 129 27 132 27 135.5 27.6 135.9 27.6
17.1 12 12 17 13
NA 5 5 5 6
NA 1 0.5 3 2
NA NA NA 4 5
1 and 4.
nton, Alberta
000–2002
Vienna
2003–2008
Vienna
2005–2008
Sweden
995–2008
Sweden
2005–2008
10.9 3.7 3.1 2.4 3.5
5.0 5.4 5.2 2.9 1.5
1.7 1.4 1.6 0.6 0.8
3.4 6.5 4.7 6.5 5.7
NA NA NA 10.9 10.4
1,310 patients. §Data available for 5,941 patients (2007–2008). Data available for 5,721 patients05
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882incidences of major adverse outcomes (mortality of 3.8%,
stroke of 1.8%, and reinfarction of 0.8%). The higher
in-hospital and 1-year mortality in patients who received
PHL in Sweden, relative to PHL in other jurisdictions may
be partially explained by a 5-year difference in mean age.
Overall, the relatively low incidences of major adverse
outcomes following PHL suggested that this reperfusion
strategy could be administered safely and effectively by
healthcare professionals of diverse trainings and expertise.
PHL should not be viewed as an alternate option, but
rather as a complementary reperfusion strategy to primary
PCI for patients with STEMI. An ideal PHL program
would incorporate formal protocols that identify patients
who would benefit from direct transport for primary PCI
where appropriate and those who would benefit from very
early FL. This would need to take account of who the
patient is (i.e., patient characteristics), where the patient is
(i.e., distance from a PCI-hospital), what is available for
treatment, and how soon the patient presents after onset of
symptoms. In this way, tailored reperfusion therapy would
be provided for each STEMI patient depending on his or
her circumstances.
In addition to facilitating transfer, integrated regional
networks of PCI-hospitals can be invaluable for continuing
cardiac care following PHL. After PHL, patients can be
transferred to PCI-hospitals and then triaged for selective
nonurgent PCI for patients with successful coronary flow
restoration with PHL or rescue PCI for patients who did
not have unsuccessful PHL. By expediting coronary reper-
fusion, PHL can prevent undue time delays with the
associated increased risks of mortality and irreversible myo-
cardial damage. In addition, PHL may reduce the economic
burden of STEMI by decreasing the need for urgent PCI
outside regular working hours.
Study limitations. First, comparison of morbidity and mor-
ality data across PHL programs could not be undertaken
ue to the lack of individual patient data. Second, our
escription of structures and processes of the PHL pro-
rams relied on a self-administered survey by the different
dministrators. Although we did query some inconsistencies
nd cross-check with other sources of information (27) and
ther experts in reperfusion therapy, we did not systemati-
ally validate all responses provided by the investigators.
hird, our survey did not incorporate economic and quality
ssurance aspects (e.g., paying process of the fibrinolytic
rugs, training and monitoring of outcomes). Finally, the
utcome data were derived from observational studies and
herefore were subject to all the biases inherent to this type
f study such as selection, confounding, and information
iases. Despite these limitations, we believe that the out-
ome data of PHL, as reported in this manuscript, provide
aluable information and may serve as benchmark for other
rograms of reperfusion therapy.onclusions
PHL has been successfully deployed in a wide range of
geographic territories with varying population densities;
access to PCI-hospitals and annual incidences of STEMI.
PHL systems comprise a variety of different processes that
could be adapted to local contexts. PHL can be safely
delivered by healthcare professionals with different levels of
training and expertise in a wide variety of settings. Even in
areas with rapid access to primary PCI, PHL remains a
valuable reperfusion strategy, for patients with expected
prolonged time delay from first medical contact to coronary
flow restoration by primary PCI.
Combining PHL with formal protocols for direct trans-
portation of patients to a PCI-hospital for primary PCI
would allow tailored reperfusion therapy for patients with
STEMI. Insights from a variety of international settings
may promote widespread use of PHL and increase timely
coronary reperfusion worldwide.
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